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Summary 
The process of antigen recognition depends in part on the amount ofpeptide antigen available 
and the affinity of the T  cell receptor for a particular peptide-major histocompatibility complex 
(MHC) molecule complex. The availability of  self antigen is limited by antigen processing, which 
is compartmentalized such that peptide antigens presented by MHC class I molecules originate 
in the cytoplasm, whereas peptide antigens presented by MHC class II molecules are acquired 
from the endocytic pathway.  This segregation of the antigen-processing pathways may limit 
the diversity of antigens that influence the development and selection of, e.g., CD4-positive, 
MHC class II-specific T  cells. Selection in this case might involve only a subset of self-encoded 
proteins, specifically those that are plasma membrane bound or secreted. 
To study these aspects of immune development, we engineered pigeon cytochrome c for ex- 
pression in transgenic mice in two forms: one in which it was  expressed as a type II plasma 
membrane protein, and a second in which it was targeted to the mitochondria after cytoplasmic 
synthesis.  Experiments with these mice clearly show that tolerance is induced in the thymus, ir- 
respective of antigen compartmentation. Using radiation bone marrow chimeras, we further 
show that cytoplasmic/mitochondrial antigen gains access to the MHC class II pathway by di- 
rect presentation. As a result of studying the anatomy of the thymus, we show that the amount 
of antigen and the affinity of the TCR affect the location and time point of thymocytes under- 
going apoptosis. 
A  central mechanism for the establishment of  self tolerance 
is the deletion of developmentally immature CD4/CD8 
double-positive (DP) 1 thymocytes. Antigens must satisfy sev- 
eral requirements to  affect a  state  of self tolerance.  They 
must  be  available  for processing and loading onto MHC 
class I and class II molecules, and they must be processed to 
peptides that bind and stabilize  MHC molecules. 
Exogenous and cell surface-associated antigens gain access 
to the endocytic compartment, where they are degraded and 
associate  with MHC  class II  (1-4).  These MHC  class II- 
peptide complexes are most often recognized by CD4-pos- 
itive helper T  cells. Peptides from endogenous proteins are 
usually presented on MHC  class I  and most often recog- 
nized by CD8-positive T  cells. Most antigens seem to fol- 
low this rule.  An  increasing body of data produced in in 
vitro systems shows, however, that proteins synthesized in- 
tracellularly in APC may also associate  with MHC class II 
1Abbreviations used in this paper: DP, double positive; ePCC, endogenous 
form of PCC; mPCC, membrane-associated  PCC; PCC, pigeon cyto- 
chrome c; PPD, purified  protein derivative;  SP, single positive. 
(2, 3,  5-12).  It therefore seems that cytosolic proteins can 
also gain access to the MHC class II compartment through 
pathways that are incompletely characterized. One pathway 
proposed is autophagy, and this may drive cytosolic com- 
ponents into the late endosomal or lysosomal compartments 
(13,  14).  Another possibility is  that  endogenous  antigens 
may be directed to the class II pathway in phagocytic cells 
via  the  engulfment  of apoptotic  cells.  The  relevance  of 
such "alternative" pathways in T  cell development is not 
well characterized, but is of considerable importance since 
this would mean that endogenous proteins can shape  the 
Th repertoire. 
To address  these questions, we generated two transgenic 
mouse lines that express pigeon cytochrome c (PCC)  en- 
dogenously (ePCC) or on the cell surface (mPCC)  in the 
thymus. Cytochrome c is normally synthesized in the cyto- 
sol and is targeted into the intermembrane space,  where it 
will complex with the respiratory chain proteins located on 
the inner mitochondrial membrane (15).  Using an H-2K  b 
promoter construct, we expressed PCC representing a cy- 
tosolic/mitochondrial neo-self antigen  in  the  thymus  of 
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placing the amino-terminal 19 amino acids with the leader/ 
transmembrane  signal anchor sequence from the influenza 
hemagglutinin type II membrane protein. We predicted that 
this modification would yield a  type II membrane-bound 
protein on the cell surface and on the inside of an endoso- 
mal vesicle. Using these mice together with transgenic mice 
expressing a TCR  specific for PCC peptide 88-104, we an- 
alyzed the induction of Th tolerance. 
A second issue in the induction of tolerance concerns the 
timing of deletion.  In some  models of negative selection, 
the developing T  cells are deleted as early DP thymocytes 
in the proximal cortex, whereas in other models, the dele- 
tion  occurs  later  at  the  DP  to  single-positive  (SP)  stage 
when  the cells are at the cortical-medullary  junction.  One 
possibility is that the affinity of the interaction between the 
TCR  and the MHC-peptide complex determines the time 
point of deletion. Using another PCC-specific TCR  trans- 
genic mouse line that  expresses a  receptor with  a reduced 
affinity, we were able to directly test and visualize the avid- 
ity model of negative selection in vivo. 
Materials and Methods 
Transgenic Mice.  The synthetic PCC gene was a generous gift 
from Dr. F. Sherman (University of Rochester, Rochester, NY) 
(16). It was cloned as a BamHI fragment into the expression vec- 
tor pES4  (reference  17  and  Fig. 2).  Vector sequences were re- 
moved by a NotI/XhoI  digest. Injection of this construct into 
(C57BL/6 SJL) oocytes yielded the SPK (ePCC) line, which was 
established to have integrated the PCC gene only on one chro- 
mosome.  The second PCC  construct targeted PCC  to the cell 
surface  by replacing the  NH2-terminal mitochondrial targeting 
sequence with the influenza neuraminidase type II signal anchor 
(a kind gift from Dr. D. Donaghue, University of California, San 
Diego). The modified PCC  gene was cloned as a BamHI frag- 
ment into pES4, and vector sequences were removed by a ClaI/ 
NotI digest. The RO  (mPCC)  founder line was chosen for fur- 
ther investigation. Transgenic  offsprings were identified by Southern 
analysis  of tail biopsies. AD10  and AND  TCR  transgenic mice 
have been described previously (17,  18). 
Northern Analysis.  Northern blots were performed as described 
by Maniatis et al. (19). Total RNA was extracted from the tested 
tissues using TRIZOL reagent (GIBCO BRL, Gaithersburg, MD), 
and 20 b~g/lane was resolved through agarose/formaldehyde de- 
naturing gels. Autoradiographs were exposed for 8 h. LPS blasts 
were prepared by incubating spleen cells in Click's EHAA me- 
dium supplemented with 10 -6 M 2-ME, penicillin/streptomycin, 
glutamine, 10% FCS, and 20 p,g/m] LPS for 48 h. Blast cells were 
then purified over a Ficoll gradient. 
lmmunofluorescence Microscopy.  Correct cellular localization of the 
transgenes was confirmed by transient transfection of Cos7 and 
HeLa cells with FLAG-tagged PCC gene variants: The 5' end of 
both PCC  gene variants were modified using appropriate PCK 
primers to clone the genes in frame into the multiple cloning site 
of the plasmid pCMV-FLAG-2c (Eastman Kodak Co., Rochester 
NY).  This resulted in the NH2-terrninal addition of a DYKD- 
DDDK peptide FLAG tag that could be detected with the mAb 
M2 (Kodak). Transcription was driven by the human CMV pro- 
moter.  Cells were  grown  on  cover slides  for 24  h  in  six-well 
plates and transfected with Lipofectamine (GIBCO BRL). After a 
total incubation time of 48 h, the cells were fixed with 95% etha- 
nol/5% acetic acid, and FLAG-tagged protein was detected using 
the mAb M2 and secondary FITC-labeled goat anti-mouse antibod- 
ies (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). 
Proliferation Assays.  For secondary in vitro assays, 50 p~g of PCC 
protein (Sigma Immunochemicals, St.  Louis)  emulsified in CFA 
were  injected into  one  hind foot pad.  After 7  d,  the  draining 
popliteal and inguinal lymph nodes were collected and minced 
into a single-cell suspension. 3-5  ￿  105 nylon wool-enriched T 
cells  were  cocultured  in  Click's EHAA  medium  supplemented 
with 10 -6 M 2-ME, penicillin/streptomycin, glutamine, and 10% 
FCS. As a source ofAPCs, 5 ￿  106 irradiated (3,500  fads) B10.A 
spleen cells were added. APC were pulsed with the indicated doses 
ofPCC peptide 88-104 or with 50 I.Lg/ml purified protein deriv- 
ative (PPD) to control for priming. After 3 d,  1 p,  Ci [3H]thymi- 
dine was added to the cultures and incubated for another  16 h. 
Cells  were  harvested,  and  the  incorporated  radioactivity was 
counted on a liquid scintillation [3 counter. 
FACS  ~ Analysis.  Stainings were performed in PBS contain- 
ing 2%  FCS, 0.1%  sodium azide, and  10 mM EDTA  using the 
following antibodies: anti-CD4  PE,  anti-CD8  FITC, and  anti- 
CD8  tricolor (all from Caltag Laboratories, San  Francisco, CA). 
Transgenic TCR chains were detected with KJ25 (anti-V[33  [20]) 
and RR8  (anti-Veil1; a  generous gift from Dr.  O.  Kanagawa, 
Washington  University,  St.  Louis,  MO)  culture  supernatants. 
FITC-conjugated goat anti-hamster (for KJ25)  and goat anti-rat 
(for RIK8)  were used as second stage antibodies. 10,000  live cells 
were collected on a FACScan  |  (Becton Dickinson & Co., Moun- 
tain View, CA) and analyzed using CellQuest software (Becton 
Dickinson & Co.). 
In Situ  TUNEL Assays.  TUNEL assays were performed as de- 
scribed previously (21).  Briefly, thymi were embedded in OCT 
(Miles, Inc., Kanakee, IL) and frozen tissue sections were prepared 
onto microscope slides, dried for 2 d at 4~  fixed in acetone, and 
endogenous peroxidase was  quenched  by  incubation in  0.01% 
H202, 50 mm Tris buffer, 150 mM NaCI. After washing, digox- 
igenin-labeled dUTP  (Boehringer Mannheim Corp., Indianapo- 
lis, IN) was incorporated into DNA strand breaks using terminal de- 
oxynucleotidyl  transferase (TdT; Promega, Madison, WI). Apoptotic 
cells were detected with sheep Fab antidigoxigenin (Boehringer 
Mannheim) followed by incubation with peroxidase-coupled  rab- 
bit anti--sheep IgG F(ab)2-specific antibodies (Jackson ImmunoRe- 
search).  Sections were developed with amino-ethyl-carbazol so- 
lution and counterstained with Meyer's hematoxylin. 
In Situ Hybridization.  In situ hybridizations were prepared ex- 
actly as described previously (22).  3SS-labeled antisense and sense 
riboprobes were transcribed from both directions using the PCC 
gene cloned into pBluescript SK II. Frozen sections were hybrid- 
ized with the sense and antisense riboprobes. Exposures were per- 
formed at 4~  in the dark for 2 wk before development. 
Bone Marrow Chimeras.  Bone marrow was collected from the 
tibia and femur of donors and in vitro-depleted ofT cells by two 
rounds of treatment with T24 (anti-Thyl) antibody plus comple- 
ment.  1-2  ￿  107 bone marrow cells were injected intravenously 
into irradiated (1,050  rads) recipients. Recipients were previously 
injected with 200 I_tg i.p, ofPK136 (anti-NKl.1) ammoniumsul- 
fate-precipitated ascites  fluid 3  and  1 d before transfusion. Ani- 
mals were left for reconstitution for the indicated amounts of time 
with 25 mg/liter neomycin sulfate and 13 mg/liter polymyxin B sul- 
fate supplemented to their drinking water for the first 3 wk. Chi- 
merism of mixed bone marrow  chimeras was determined after 
3-4 wk by collecting blood from the tail vein into FACS  ~ buffer. 
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(both from Caltag). After incubation, red cells were lysed and the 
degree of chimerism was determined by gating on B220-positive 
live B cells and monitoring the expression of H-2E. 
Results 
Generation  of  Intracellular and  Cell  Membrane-associated, 
PCC-transgenic Mice.  The wild-type PCC transgene was ex- 
pressed in lymphoid tissues, including the thymus, using the 
pES4  expression vector (Fig.  1).  A  second  construct was 
generated to target PCC to the cell surface: the mitochon- 
drial targeting sequences are located at the amino terminal 
end  and  within  the  protein  (15,  23).  The  NH2-terminal 
mitochondrial targeting sequence was replaced with the in- 
fluenza neuraminidase type II signal  anchor. This modified 
PCC gene was also cloned into the H-2K  b expression vec- 
tor. SPK mice had integrated the ePCC whereas RO mice 
were transgenic  for mPCC.  Northern Blot analysis revealed 
that the transgenes were expressed in thymus, spleen, and 
LPS-stimulated B cells (Fig. 2). mPCC mice expressed sig- 
nificantly higher mRNA  levels than  ePCC  mice.  Trans- 
genic mRNA was readily detected in LPS blasts and in spleens 
of  ePCC  mice  after  prolonged  exposure  overnight  (not 
shown). 
Cellular Localization.  All  the  antibodies  we  tested  cross- 
reacted on mouse cytochrome c, thus preventing us fi'om di- 
recdy examining the intracellular localization of transgenic 
PCC expression. To circumvent this problem, we generated 
constructs in which the FLAG tag was fused to the NH  2- 
terminal end of the two PCC variants. Cos7 cells (Fig. 3) and 
HeLa  cells  (data  not  shown)  were  transiently  tranfected 
and  analyzed by fluorescence microscopy using the  FLAG- 
specific  mAb  M2.  The  staining  pattern  of FLAG-tagged 
mPCC-transfected cells was consistent with localization to 
the cell surface and to an intracellular organelle (Fig.  3 A, 
see legend).  The FLAG-tagged ePCC  construct gave rise 
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Figure 1.  PCC transgene constructs. The synthetic PCC gene (cytoso- 
hc/mitochondrial  localization)  was  cloned  into  the  expression  vector 
pES4, providing the H-2K  b promoter,  the Ig heavy chain enhancer, hu- 
man [3-globin exons 2  and 3, and a poly adenylation site. In the second 
PCC  gene variant,  the NH2-terminal mitochondrial targeting sequence 
was replaced by the influenza neuraminidase type II  signal anchor to di- 
rect PCC to the cell surface. 
Figure 2.  Transgenic  PCC mP,  NA expression. Total RNA from thy- 
mus, spleen, and LPS blasts obtained  from ePCC, mPCC, and nontrans- 
genic control  mice was analyzed  by Northern  blot. To confirm  that equal 
amounts of  total RNA were loaded  in each lane, the filters  were reprobed 
with a glyceraldehyde  3-phosphate dehydrogenase-specific  probe. 
to a punctate pattern of  staining that is typical ofmitochon- 
drial localization patterns for ethanol-fixed cells  (Fig.  3 B). 
Thus,  the gene products were targeted to  the  anticipated 
cellular sites. 
Induction of Tolerance in mPCC and ePCC Mice.  To  inves- 
tigate whether both forms of PCC were able to induce tol- 
erance, proliferative responses to  PCC  were measured in 
secondary in vitro cultures. PCC-transgenic mice and con- 
trol httermates were inoculated with PCC protein emulsi- 
fied in CFA, and enriched T  cells from the draining lymph 
nodes were explanted to tissue  culture 7  d  later.  Cultures 
were stimulated with various concentrations of PCC pep- 
tide or a single dose of PPD. Proliferation was greatly re- 
duced in ePCC mice and comparable to background levels 
in mPCC mice (Fig. 4). The response to PPD was equiva- 
lent in PCC-transgenic and control mice (see Fig. 4 legend). 
Thus, ePCC and mPCC were both effective at inducing a 
state of tolerance. The quantitative difference in the degree 
of responsiveness presumably resulted from the amount of 
expressed antigen-MHC complexes on the surface of  APCs. 
We  could  not determine whether  this  resulted  from  the 
difference in intracellular localization, the level of expressed 
antigen, or both. 
To determine the stage of tolerance induction in the two 
PCC-transgenic mouse hnes, they were crossed with AD10 
TCR. transgenics that bear a receptor specific for PCC pep- 
tide 88-104 on H-2E  k (17,  18). Comparison ofthymocytes 
from AD10￿  double  transgenics  with  AD10  single 
transgenic animals revealed that expression of  both forms of 
PCC resulted in a largely reduced population of CD4  SP 
thymocytes (Fig. 5). Transgenic V0tl I and V133 TCP, chain 
expression levels were unaltered on the DP populations (data 
not shown); however, the CD4 SP thymocytes that escaped 
clonal deletion displayed biphasic and somewhat reduced pat- 
terns of staining for Votl 1 and V[33 (Fig. 5). This is indica- 
tive of cells that express endogenous T  cell receptor chains. 
It is even possible that all of the CD4 SP thymocytes ex- 
press at least one nontransgenic TCR chain. When analyz- 
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Figure  4.  Proliferative responses of ePCC-  and  mPCC-transgenic 
mice. Secondary in vitro assays were performed with lymph node cells 
obtained from ePCC, mPCC, or nontransgenic  littermates inmmnized 
with PCC protein or PBS as control emulsified  in CFA. Responses of 
ePCC and mPCC mice were measured in two separate experiments at 
the indicated PCC peptide concentrations.  PPD responses measured to 
control for priming were in similar  ranges within experiments:  ePCC and 
controls, 140,000-170,000 cpm; mPCC and controls, 90,000-110,000 cpm. 
Figure 3.  Cellular  localization  oftransgenic  mPCC and ePCC. (A) NH  2- 
terminal addition of the FLAG tag to the mPCC gene variant (FLAG- 
mPCC) resulted in ceU-surface staining  patterns of transiently  transfected 
Cos7 cells. Punctate staining  is cell surface associated and could be distin- 
guished from intracellular  staining by scanning through the focal plains. 
lntraceUular  diffuse staining  peripheral to the nucleus  may represent stain- 
ing of the endoplasmatic  reticulum.  (B) Localization  ofePCC to mitochon- 
dria was confirmed  by detection of an NHz-terminally  FLAG-tagged  ePCC 
(FLAG-ePCC) construct. Positive  cells shown here are embedded within 
a confluent cell layer serving  as background  control staining. 
ing peripheral T  cells from the lymph nodes of double trans- 
genic mice, we found that percentages of mature CD4 T  cells 
were reduced somewhat more in AD10￿  (from 41% 
in AD10 to  14% in AD10XmPCC) than in AD10￿ 
(from 41% in AD10 to 20% in AD10￿  mice (data 
not  shown).  The  CD4-positive cells  displayed TCt<  ex- 
pression patterns similar to the mature thymocytes that had 
escaped deletion. The cells that had escaped clonal deletion 
were still responsive in primary in vitro proliferation assays, 
although 10 (AD10XePCC) to 100 (AD10XmPCC) times 
higher PCC doses were required for stimulation compara- 
ble to T  cells from AD10 TCI< single transgenic mice (data 
not shown).  Thus,  central tolerance was  induced in both 
mouse lines, resulting in a highly diminished population of 
antigen-reactive CD4 SP  cells.  There was no evidence of 
autoimmunity or compromised health in the double trans- 
genic or immunized mice. 
Early  vs.  Late  Deletion  Correlates  with  Cortical  vs.  Cortico- 
medullary Apoptosis.  To  more  closely  define  the  stage  at 
which self reactive thymocytes were  deleted,  absolute cell 
numbers of thymocyte subpopulations were calculated. This 
revealed a reduction of 61  _+  13% of DP in AD10￿ 
vs. 4.0 --- 3.8% of DPs in AD10XePCC mice, respectively. 
Since the CD4 SP populations were affected to similar de- 
grees in both lines (deletion of 96  -+ 2% in AD10￿ 
and 83  +  4% in AD10XePCC), we  can deduce that DP 
thymocytes are eliminated at a relatively earlier stage in mPCC 
compared to ePCC transgenics. 
At least two possibilities could account for this difference. 
First, positioning effects  of the transgene could result in the 
expression oftransgenic PCC in different regions of the thy- 
mus.  Second, toleragen expression levels may dictate time 
point and site of deletion. To investigate whether expres- 
sion patterns were responsible for early vs. late deletion and 
whether the  time point of deletion was manifested in the 
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Figure  5.  Reduction of CD4SP thy- 
mocytes in AD10￿  double trans- 
genic mice. Thymocyte from  AD10 
TCk, AD10￿  and AD10XmPCC 
transgenic mice were triple stained for 
CD4, CD8, and V133 or Vall. Trans- 
genic TCR levels were determined by 
gating  on  the  CD4  SP  population. 
Numbers in  quadrants represent per- 
centages of the respective populations. 
Shown are plots representative of five 
independent experiments. 
site of deletion, we determined where in the thymus self- 
reactive thymocytes were eliminated. In situ TUNEL assays 
performed on  thymi of double  transgenic  mice to  detect 
apoptotic  thymocytes showed  that  cells  which  had  frag- 
mented their DNA appeared in the cortex of early deleting 
mPCC mice, whereas such cells were found at the cortico- 
medullary junction and in the medulla of late deleting ePCC 
mice  (Fig.  6,  A  and  B).  Thus,  relatively early deletion  of 
DP correlated with cortical apoptosis, whereas late deletion 
paralleled with cortico-medullary and medullary apoptosis. 
To  determine  the  anatomical location  of PCC  expres- 
sion within the thymus, in situ hybridization studies were 
carried out using a PCC-specific probe on thymic sections, 
Fig. 7 A-C depicts autoradiographic sections showing that 
PCC is expressed in the cortex and medulla of both PCC- 
transgenic mouse lines, albeit at lower levels in ePCC mice. 
Since  thymocytes also  express  the  transgenes,  part  of the 
signal seen in this experiment probably originates from thy- 
mocytes that presumably do not directly function as APCs. 
To address this issue  further, mPCC and ePCC-transgenic 
mice were lethally irradiated  and reconstituted with bone 
marrow from normal mice. These mice were analyzed after 
4 wk and typed for chimerism. In the thymus of these radi- 
ation  chimeras,  the  only  cells  that  could  express  a  PCC 
transgene  message would  be epithelial  cells  and  some ra- 
dioresistant  macrophages.  The  expression  patterns  were 
identical to those of unmanipulated transgenic animals. As 
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expected, however, the overall signal was reduced (data not 
shown).  Compared to the cortical expression levels, med- 
unary expression was lower in both lines and experiments. 
Thus,  at least for the  unmanipulated  thymus  and  the  ra- 
dioresistant  cells  of the  thymus,  there  was  no  anatomical 
difference in the expression of ePCC and mPCC. 
The  above results  argue  for the  second  possibility  that 
the level of antigen expression can account for early vs. late 
deletion.  Indeed, R.NA expression levels as determined by 
Northern blot analysis were higher in mPCC than in ePCC 
mice (see Fig. 2). Taken together, early deletion resulted in 
apoptosis in the cortex and the medulla, whereas late dele- 
tion promoted the  elimination  of thymocytes at the  cor- 
tico-medullary junction  and  in  the  medulla.  Presumably, 
the time point of deletion was influenced by the levels of 
PCC-bound MHC class II molecules. 
Influence of TCR Affinity on  Time  Point and Site of Dele- 
tion.  Our results are consistent with the process of nega- 
tive selection depending in part on the level of antigen pre- 
sentation,  and thus  the  avidity of the interaction between 
the TC1L and the peptide-MHC complex. Another com- 
ponent  that  determines the  avidity of the  interaction be- 
tween the TCR. and the MHC-peptide complex is the af- 
finity of the TCR itself.  AND TCR-transgenic mice bear 
an ot chain that differs in one amino acid in the V-J junc- 
tion with respect to the original AD10  receptor (17).  We 
have found that 70% of the AD10 DP thymocytes could be Figure 6.  Detection of apoptotic cells in thymic sections by in situ 
TUNEL assay. (A) AD10XmPCC transgenic  thymus section. Dark red 
staining  represents cells that have fragmented their DNA. Most apoptotic 
cells are detected in the cortex (cor), but some are also visible  in the me- 
dulla (reed). (B) AD10￿  thymic section. Apoptotic  cells appear at 
the cortico-medullary  junction and in the medulla. (C) Cortico-medul- 
lary apoptosis in AND￿  mice. AD10 TCR- and AND TCR.- 
transgenic control sections showed extremely low background staining 
scattered in the cortex and medulla. Sections represent stainings from 
three to four different  mice. ￿ 
deleted after a  single injection with 750  Ixg i.v.  of whole 
PCC protein, whereas not even 1.6 mg of protein was suf- 
ficient to detect the deletion of AND DP thymocytes (data 
not shown).  Similar levels of deletion as  in AD10  TCR 
transgenics could be  obtained in AND  TC1L  transgenics 
only after three daily injections of 750 p~g of PCC protein. 
This shows that the AND-transgenic thymocytes are less sen- 
sitive  to  antigen  administration than  AD10  thymocytes, 
and would appear to imply that the single amino acid dif- 
ference in the AND TCR causes a reduction of the affinity 
Figure 7.  Transgene  expression  patterns in ePCC and mPCC mice. In 
situ hybridizations  were performed on thymic  sections  from (A) mPCC and 
(B) ePCC mice, using a PCC-specific  probe. Dark grains represent trans- 
genic mRNA. Transgenic  PCC is expressed in the cortex (cor) and at lower 
levels in the medulla (med) of both mouse lines. Overall staining  is lower 
in ePCC animals. (C) Nontransgenic  littermate. Identical  background stain- 
ing as in C was obtained  with the sense riboprobe on all sections. ￿  1,000. 
for MHC/antigen when compared with the AD10 TCR 
transgenics. To investigate the  influence of the  difference 
between AD10 and AND mice on the time point and site 
of deletion, AND  mice were  bred with mPCC  mice.  In 
such double transgenic animals, negative selection occurred 
very late in the DP stage  (24): deletion of DP thymocytes 
was  marginal in AND￿  mice  while  absolute  cell 
numbers of the CD4 SP population were reduced by 75%. 
Fig. 6  C shows that apoptotic cells appeared at the cortico- 
medullary junction in AND￿  mice, and not in the 
cortex  as  in  AD10XmPCC  mice  (see  Fig.  6  A).  Thus, 
the self-reactive TCR expressed by a thymocyte influences 
the time point and site of deletion. 
Endogenous  Self Antigen  Can be Directly Processed to Induce 
Negative Selection.  In principle, antigen can be  processed 
2622  T Helper Cell Tolerance Induction by Endogenous Antigen within  a  cell and presented  directly,  or it can be  acquired 
indirectly  via  engulfment  of  apoptotic  cells  (e.g.,  thy- 
mocytes), cellular debris, soluble shed, or secreted proteins. 
In particular,  we  were  interested  in  determining  whether 
ePCC is presented directly to cause negative selection.  To 
investigate  this  question,  the  following bone marrow chi- 
meras were generated: H-2Ek-positive ePCC, mPCC, and 
nontransgenic littermates  were irradiated  and reconstituted 
with H-2  b (H-2E  ~  AD10 TCP,-transgenic  bone marrow 
and analyzed 3-5 wk later (Table  1). In these radiation chi- 
meras, transgenic ePCC can be presented only if it is directly 
processed and  presented  by radioresistant  macrophages  or 
thymic epithelial cells.  Since thymic macrophages are largely 
MHC class II negative (25, 26), the most likely APC would 
be  epithelial  cells.  The  experiments  presented  in  Table  1 
show that the CD4 SP TCP,.-transgenic thymocyte popu- 
lation was significantly reduced in ePCC and mPCC recip- 
ients  as compared with controls.  Since we find it unlikely 
that  epithelial  cells  could  acquire  PCC  exogenously  in 
these radiation chimeras, we deduce that ePCC can be di- 
rectly  processed  onto  MHC  class  II  and  effectively  pre- 
sented by thymic epithelial cells (see Discussion). 
Reuptake of Self Antigen Results in Clonal Deletion.  A  sec- 
ond set of bone marrow chimeras were tested for the possi- 
bility that PCC can be directed to the endocytic processing 
pathway by the  reuptake  of antigen  derived from thymo- 
cytes undergoing apoptosis (21) or the reuptake of shed an- 
tigen. A mixture of two types of bone marrow was injected 
into PCC-negative, H-2Ek-positive recipients, The first type 
was taken from mice that expressed PCC and were H-2E  k- 
negative. This bone marrow provides PCC-transgenic thy- 
mocytes that can be engulfed and could serve as a source of 
shed antigen. Any APCs that develop from this bone mar- 
row, however, will be unable to present PCC because they 
do not express H-2E  k. The other type of bone marrow was 
harvested from mice that expressed H-2E  k, but did not ex- 
Table  1.  Clonal Deletion after Direct Processing of Endogenous 
PCC 
% CD4 SP 
Donor  Recipients*  +  SEM* 
(I-E-)  (I-E  k)  n  (% deletion) 
Experiment 1 
Experiment 2 
TCP,.  Non-Tg  3  39.7  +  6.3 
TCR  ePCC  3  17.0 +  1.5 (56%) 
TCP,  mPCC  3  23.3 -+ 2.6 (41%) 
TClk  Non-Tg  4  21.9 +_ 1.9 
TCR  ePCC  3  11.4 +  1.1 (48%) 
TCI<  mPCC  4  12.2 +  1.0 (46%) 
*H-2Ek-positive recipients were transfused with 107 bone marrow cells 
obtained  from  AD10  TCR.-transgenic,  H-2E-negative  donors, and 
were left for reconstitution for 5 wk in experiment 1 and for 3 wk in 
experiment 2. 
*Thymocytes from recipients were stained for CD4 and CD8, and the 
percentages of CD4 SP thymocytes were determined by flow cytome- 
try. Absolute cell numbers did not vary significantly. 
press PCC. This bone marrow provides phagocytes that can 
engulf and present PCC derived from the first marrow type. 
Recipients  expressed  the  MHC  molecules  appropriate  for 
the  presentation  of PCC.  After  reconstitution  for  8  wk, 
chimeras were challenged with PCC protein emulsified in 
CFA, and PCC-specific proliferative responses were mea- 
sured in vitro. The experiment depicted in Fig. 8 shows that 
the presence of H-2Ek-negative, PCC-transgenic bone mar- 
row resulted  in  reduced proliferative  responses,  regardless 
of whether ePCC  or mPCC marrow was used.  Although 
the degree of chimerism was lower in mice receiving mPCC 
marrow,  the  reduction in the response was comparable to 
ePCC chimeras, probably resulting from higher mPCC ex- 
pression levels. Thus, reuptake of antigen can participate in 
the induction of Th tolerance. 
This  issue  was  alternatively  addressed  by  producing  a 
similar  set  of chimeric  mice  in  which  all  the  T  cells  ex- 
pressed  the  AD10  TCR.  Tolerance  induction  could thus 
be monitored by flow cytometry. Table 2  shows that two 
out of four recipients  that had received  ePCC bone mar- 
row showed some reduction in the percentage of CD4 SP 
thymoctes 5 wk after reconstitution. All recipients that were 
transfused  with  mPCC  bone  marrow showed  a  small but 
significant reduction in the CD4 SP population. We inter- 
pret  these  experiments  to  indicate  that  reuptake  of cell- 
Donor  B6 + B/A  ePCC + B/A 
bone marrow:  (I-Eo)(I-Ek)  (I-Eo)  (I-Ek) 
20000 ￿84 
%  Chlmerlsm  :  50 : 50  50 : 50 
0  ...... 
Figure 8. 
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Reduction of proliferative responses in mixed bone marrow 
chimeras. Lymph node cells from mixed bone marrow chimeras that had 
been left for reconstitution for 8 wk were injected into the hind footpad 
with PCC protein emulsified in CFA and assayed in secondary in vitro 
proliferation assays. Because of the low number of cells recovered, puri- 
fied cells were stimulated with the one indicated dose of PCC peptide or 
were left unstimulated for background  proliferation. Printing efficiency  was 
determined by measuring the proliferative response to 50 I~g/ml PPD and 
was comparable in all mice tested, ranging from 45,000-65,000 cpm; rel- 
atively lower PPD counts did not  correlate with  corresponding lower 
PCC-specific proliferation. Points represent results from triplicate wells per 
mouse. Bone marrow composition and degree of chimerism are indi- 
cated. B6, C57B1/6 bone marrow (H-2E~  B/A,  (C57B1/6￿ 
bone marrow (H-2Ek). 
2623  Oehen et al. Table 2.  Deletion  after Reuptake of Cell-derived Self Antigen 
Bone 
marrow  % CD4 Spa 
Bone marrow 1  2  R.ecipient*  thymocytes 
(I-E-)  (I-E+)  (I-E+)  ,  (% deletion) 
tion of these experiments is that both ePCC and mPCC can 
be presented without secretion or reuptake. Since epithelial 
cells  have previously been  shown  to  mediate  negative  se- 
lection  inefficiently  (30),  the  fact that we  see negative  se- 
Average  lection in this experiment is highly significant. 
-+ SEM  The experiments in which reuptake was needed to present 
antigen indicated that representation is an inefficient means 
27.5  of inducing  negative  selection  (Table  2).  Suhr  et al.  have 
29.3  recently shown  that a large number,  if not all,  thymocytes 
23.0  that die in the thymus are engulfed by thymic macrophages 
21.0  25.2  +  1.9  (2l).  These  macrophages  could  potentially  present  PCC, 
26.1  irrespective  of  its  original  cellular  locahzation.  Thymic 
19.5  (23%)  macrophages, however, are very poor at inducing tolerance 
and express low levels of MHC  class  II (31,  32).  Conceiv-  18.7  (26%) 
ably, cellular material may be released as degradation prod- 
25.9  22.5  +  2.0  ucts from dying thymocytes or thymic macrophages; how- 
15.5 (38%)  ever,  the  process  of apoptosis  is such  that  the  contents  of 
16.4  (35%)  dying cells are not usually released into the tissues (33). A1- 
17.0 (33%)  ternatively,  peripheral  APCs  that  have  engulfed  apoptotic 
17.7 (30%)  16.7  _+ 0.5  immune cells expressing PCC may recirculate into the thy- 
mus to induce tolerance. 
What  is the  primary means  of presentation  in  unirradi- 
ated  ePCC  and  mPCC  mice?  The  experiments  published 
to date support dendritic  cells as the most likely presenting 
cells  to  account  for negative  selection  (34-36).  Based  on 
the  interpretation  of the  experiments  in  this  report,  the 
most likely route  of tolerance  is the  direct presentation  of 
MHC  class II-bound PCC by dendritic  cells. 
Stockinger  et al.  produced  radiation  chimeras  in  which 
pro-C5  was  expressed  endogenously  within  macrophages, 
but  C5 was not secreted.  Pro-C5  was not presented  in an 
antigenic  form associated with  class  II molecules.  In these 
mice,  there  was no  evident  tolerance.  Assuming  that  thy- 
mic macrophages also expressed pro-C5,  these mice would 
not be expected to exhibit tolerance to C5 for two reasons: 
macrophages  are  poor  in  the  induction  of tolerance,  and 
endogenously synthesized pro-C5 is not presented by MHC 
class  II.  Another  likely  explanation  for  the  apparent  dis- 
crepancy  between  the  results  presented  here  and  those  of 
Stockinger  et  al.  is  that  mitochondrial  cytochrome  c and 
pro-C5 may simply have a different access to the class II path- 
way. There are numerous examples of cytoplasmic antigens 
that apparently gain direct access to MHC  class II presenta- 
tion in vitro,  and this may be protein and  expression level 
dependent  (2, 3, 5-12). 
The  pathway  of cytoplasmic  or  nfitochondrial  antigen 
presentation by MHC  class II molecules is thus far unchar- 
acterized.  Loss et al. have previously reported the existence 
of an  alternative  processing  pathway  that  allows  endoge- 
nously synthesized L d peptide to traffic onto MHC  class  II 
(12). Another potential processing pathway particularly rel- 
evant  to  mitochondria  is via the  formation  of autophago- 
somes  (37,  38).  While  this  is  a  potential  mechanism  for 
transport of mitochondrial or cytoplasmic proteins into the 
class  II pathway,  most studies are consistent  with  an inter- 
section  of autophagosomes  and  lysosomes,  a  point  in  the 
endocytic  pathway  that  is  believed  to  be  later  than  the 
MHC  class II compartment (1). 
T Helper Cell Tolerance Induction by Endogenous Antigen 
TCR  TCR. 
(TCR. X ePCC)  TCR 
(TCR. X mPCC)  TCR. 
*Recipients  were transfused at a ratio of 1:1  with  I07 bone marrow 
cells from each donor and analyzed 5 wk later. Chimerism was 50:50% 
in  all  recipients  and  was  determined  as  described in  Materials and 
Methods. 
r  were stained for CD4 and CD8,  and the percentages of 
CD4 SP cells were determined. 
associated or shed self antigen can play a part, albeit possibly 
minor, in the induction  of Th tolerance to self antigens. 
Discussion 
This study was aimed at investigating parameters govern- 
ing the induction of Th tolerance, including the cellular lo- 
calization  of self antigen,  toleragen  expression  levels,  and 
TCR  affinities,  and  correlating  these  effects with  the  time 
point and site of deletion in vivo. 
The  data indicate  that antigen  may be directed  into  the 
class II processing pathway primarily via a direct route within 
the presenting cells and perhaps secondarily via reuptake of 
apoptotic  cells,  cell debris,  or shed  antigen.  In the  experi- 
ment described in Table 1, the only source of PCC are the 
radioresistant cells of the thymus. The PCC-transgenic mice 
were  irradiated  with  1,050  rads,  and  this  dosage  has been 
shown to rapidly eliminate the bone marrow-derived APC 
of host origin, such as dendritic  cells and macrophages  (27, 
28).  Since  there  are  no  radioresistant  follicular  dendritic 
cells known to reside in the thymus that could trap antigen 
in  antibody-antigen  complexes,  the  only  presenting  cells 
remaining after irradiation that express MHC  class II mole- 
cules would  be epithelial  cells.  These epithelial  cells could 
not  harbor peptides  acquired  from exogenous  sources be- 
fore or as a  consequence  of irradiation  for as long as  5  wk 
since  the  half life of MHC  class  II-peptide complexes has 
been shown to he  13 h  (29). Thus, the simplest interpreta- 
2624 Toleragen expression levels seem to play a role in deter- 
mining  the  developmental  stage  and  corresponding  ana- 
tomical site  of thymocyte deletion.  In AD10￿  mice, 
deletion occurred within the DP subset, and this correlated 
with an increase in apoptosis within the cortex. In contrast, 
deletion in AD10XePCC transgenics  occtlrred later,  since 
there was a barely detectable decrease in the number of DP 
thymocytes, and increased apoptosis was found only at the 
cortico-medullary junction.  There  are two possible  expla- 
nations to account for this difference. One is that the levels 
of antigen presentation  are lower in ePCC mice,  and  this 
level is only sufficient to cause deletion  in late DPs when 
the  TCP, is upregulated.  A  second possibility is that  anti- 
gens are expressed in anatomically different sites. We felt we 
could eliminate the latter possibility, since in situ hybridiza- 
tion showed consistent  expression  throughout  the  thymus 
for both transgenes.  We thus conclude that a difference in 
antigen presentation levels accounts for the results.  We did 
not determine whether the diminished antigen presentation 
is caused by decreased expression, the efficiency of the pre- 
sentation pathway, or both. 
We also observed that mPCC causes a relatively early de- 
letion when crossed with AD10 TCR-transgenic mice and 
a later  deletion when crossed with the AND TCR-trans- 
genic mice.  Since we have not detected a difference in the 
levels of receptor expression in these two TCR-transgenic 
mouse  lines,  the  difference  in  the  timing  of deletion  is 
probably caused by an affinity difference in the interaction 
between the TCR and the MHC-peptide complex, the re- 
sult  of a  single  amino  acid  difference  in  the  Ix-chain  se- 
quences.  Thus,  the  timing of deletion  is a function of the 
avidity of the thymocyte-APC interaction. 
Most previous work in TCR-transgenic  mice in which 
negative  selection  to  nominal  antigen  was  examined  re- 
vealed  deletion  at  a  very early DP  stage,  whereas  studies 
with negative selection induced by endogenous superanti- 
gens have  revealed deletion late  in the life of DP thymo- 
cytes, at the transition from DP to SP. The present experi- 
ments show that the timing of deletion in part importantly 
depends  on the presentation  of the  antigenic  determinant. 
The very same TCR-transgenic mice can show an early or 
a late deletion,  depending on antigen presentation and ex- 
pression  levels.  Conversely,  the  very  same  antigen  can 
cause early or late deletion, depending on the TCR. This is 
consistent with the avidity model of negative selection. 
Taken together, we were able to show that endogenous 
cellular proteins can gain access to the endocytic processing 
pathways in vivo to help shape the Th repertoire. The uni- 
verse of self antigens inducing Th tolerance may therefore 
be  larger  than  the  set of peptides  from cell-surface  or se- 
creted proteins. Although experiments examining the pep- 
tides bound to MHC class II molecules reveal peptides from 
secreted or membrane-bound proteins (2, 7), these may re- 
flect  only the  most abundant  peptides.  In contrast,  toler- 
ance induction  may require  only a  small  number  of pep- 
tides presented per cell. 
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